Regencell Bioscience Holdings Limited — FY2022 Form 20-F
Period clarification: The filing is an annual report for the fiscal year ended June 30, 2022, with comparisons to fiscal 2021. It does not provide a standalone 2021 Q4 report or quarterly results.
Business context and reporting period
Regencell is a Hong Kong-focused, early-stage TCM bioscience company developing treatments principally for ADHD and autism spectrum disorder (ASD), and exploring a TCM treatment for COVID-19. It has not generated product revenue. Its ordinary shares trade on Nasdaq under RGC. Financial statements are prepared under U.S. GAAP and audited.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $7.62 million | $1.38 million |
| Net loss | $7.59 million | $1.35 million |
| Loss per share, basic and diluted | $0.58 | $0.13 |
| Net cash used in operating activities | $5.27 million | $0.77 million |
FY2022 operating expenses included $5.08 million of general and administrative expense and $2.51 million of research and development expense. Share-based compensation was $2.76 million in total. The filing reports no gross profit or operating margin because the company had no revenue.
At June 30, 2022, cash was $6.42 million and short-term investments were $10.00 million, for $16.42 million combined. Total assets were $18.02 million; total liabilities were $0.94 million, including $0.77 million of operating lease liabilities. The company reported no outstanding shareholder loans or convertible note at year-end. Management said available cash and short-term investments were expected to fund operations and obligations for at least 12 months.
FY2022 investing cash outflow was $10.78 million, including a $10.00 million short-term investment placement and $0.78 million of property and equipment purchases. Financing cash inflow was $22.41 million, primarily reflecting net IPO proceeds. Year-end cash increased to $6.42 million from $59,000.
Material changes versus FY2021
- Net loss increased by $6.25 million, as operating expenses rose 451% to $7.62 million.
- General and administrative expense rose to $5.08 million, driven in part by $1.5 million of share-based compensation, public-company professional fees, higher salaries, rent and business activity.
- Research and development expense increased to $2.51 million, including $1.2 million of share-based compensation and increased staffing, facilities and product-development costs.
- The July–August 2021 IPO and over-allotment generated approximately $22.67 million in net proceeds. The company also converted a $3.25 million related-party note into 342,105 shares; the remaining $431,969 shareholder loan was repaid.
- Operating lease assets and liabilities were recognized following adoption of ASC 842 in FY2022.
Outlook, risks and unusual items
- Development and regulatory risk: Three standardized TCM formula candidates were under development; none had marketing approval. The company stated it had not applied for regulatory approval and lacked commercial sales and distribution capabilities. Hong Kong manufacturing licensing and product registration, as well as evidence of safety, quality, stability and efficacy, are required before commercialization.
- Preliminary study evidence: Reported ADHD/ASD improvements came from small, uncontrolled groups—seven patients in the first study and seven in the first group of the second trial. Assessments relied substantially on parent or caregiver reports. The filing cautions that results are not controlled clinical evidence and may not predict future outcomes.
- COVID-19 initiative: The company reported 12 suspected or confirmed COVID cases treated by its TCM practitioner, with records indicating improvement after an average of five days. This is not presented as controlled clinical evidence. A 60%-owned joint venture with Honor Epic was formed to pursue COVID-related TCM activities in designated Asian and Pacific markets; commercialization and returns are uncertain.
- Funding and losses: The company has recurring losses and operating cash outflows and expects further losses before revenue. Management considered year-end liquidity sufficient for at least 12 months, while warning that future financing may be needed and could dilute shareholders.
- Governance and reporting controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at June 30, 2022. Three material weaknesses involved insufficient U.S. GAAP/SEC reporting expertise, no internal audit function, and inadequate segregation of duties. Remediation was underway; auditor attestation was not provided.
- Concentration and related parties: The founder/CEO beneficially owned 81.1% of shares. The key TCM practitioner is his father and the company’s strategic research partner. The partnership requires a donation of 3% of net revenue associated with the formulae, if generated, and reimbursement of research expenses. The filing also reports related-party rent and product-development expenses.
- Other items: The company reported $2.76 million of FY2022 share-based compensation and no material legal proceedings. It believed it was not a PFIC for FY2022, but provided no assurance. It does not expect to pay dividends in the foreseeable future.
Most important facts for investors to verify
- Whether the second efficacy trial has progressed beyond the small initial cohort, and whether larger, controlled studies support efficacy and safety.
- Current Hong Kong regulatory application status, required approvals, manufacturing plans and realistic commercialization timelines.
- Cash and short-term investment balances, cash-burn rate, and whether management’s stated 12-month funding runway remains valid.
- Progress in remediating the three material weaknesses and whether subsequent filings report effective controls.
- Terms, funding obligations, operating progress and any realized results of the 60%-owned COVID joint venture.
- Share-based compensation, outstanding options and potential dilution, alongside the founder’s voting control and related-party arrangements.